Viridian Therapeutics
VRDN
18.28
+0.06
+0.33%
Viridian Therapeutics
US · VRDN
#2731 by market cap
Listed 1970
18.28
+0.06
+0.33%
Live - 5344 symbols - heartbeat 9s ago
· 2026-10-07 21:23
After-hours
18.22
-0.33%
Overnight
18.07
-1.15%
- Market cap
- 2.07B
- P/E (TTM)i
- -5.38
- P/Bi
- 3.67
- EPSi
- -3.32
- Div yieldi
- 0.00%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on VRDN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.77, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +23,359.93% YoY
Margins
- Operating margin
- -512.91%
- Net margin
- -483.57%
Key ratios & quality
- Enterprise valuei
- 1.25B
- Altman Z-Scorei
- 4.77
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.39M | 4.46M | 1.05M | 2.96M | 1.77M | 314.00K | 302.00K | 70.85M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.05M | 11.65M | 13.27M | 25.81M | 35.18M | 95.00M | 61.08M | 95.32M |
| Research & development | 30.42M | 34.79M | 28.30M | 56.89M | 100.89M | 159.77M | 238.25M | 338.93M |
| Operating profit | -33.08M | -41.98M | -40.52M | -79.73M | -134.30M | -254.45M | -299.04M | -363.40M |
| Pretax profit | -32.70M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M | -342.60M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -32.70M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M | -342.60M |
| Basic EPS | -16 | -20 | -31 | -7 | -3 | -4 | -3 | -3 |
| Diluted EPS | -16.50 | -20.04 | -31.13 | -6.66 | -2.71 | -3.91 | -3.07 | -3.32 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 72.00K | 75.00K | 70.57M | 132.00K | 141.00K | 284.00K |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 17.10M | 20.22M | 24.32M | 33.67M | 38.68M | 54.98M |
| Research & development | 76.84M | 86.63M | 86.26M | 89.21M | 77.63M | 71.58M |
| Operating profit | -93.87M | -106.77M | -40.01M | -122.75M | -116.17M | -126.27M |
| Pretax profit | -86.91M | -100.74M | -34.60M | -120.36M | -104.90M | -127.12M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -86.91M | -100.74M | -34.60M | -120.36M | -104.90M | -127.12M |
| Basic EPS | -1 | -1 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.87 | -1.00 | -0.34 | -1.08 | -0.90 | -1.05 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 65.37M | 29.74M | 129.61M | 200.16M | 431.17M | 486.48M | 738.46M | 894.23M |
| Cash & ST investments | 62.48M | 26.85M | 127.64M | 196.97M | 424.55M | 477.37M | 717.58M | 874.65M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 66.15M | 30.26M | 131.26M | 203.71M | 435.09M | 490.42M | 742.40M | 899.42M |
| Total current liabilities | 6.73M | 10.18M | 10.67M | 13.64M | 33.35M | 26.64M | 47.87M | 70.70M |
| Short-term debt | 2.29M | 3.98M | 455.00K | 520.00K | 613.00K | 843.00K | 513.00K | 753.00K |
| Long-term debt | 8.00M | 4.33M | -- | -- | 4.65M | 20.21M | 20.58M | 49.94M |
| Total liabilities | 14,803,000.00 | 14,508,000.00 | 11,218,000.00 | 15,993,000.00 | 40,027,000.00 | 48,402,000.00 | 70,764,000.00 | 177,251,000.00 |
| Total equity | 51.34M | 15.75M | 120.04M | 187.72M | 395.06M | 442.02M | 671.64M | 722.17M |
| Retained earnings | -126.30M | -168.17M | -278.89M | -358.30M | -488.17M | -725.91M | -995.86M | -1.34B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 657.24M | 578.75M | 571.91M | 894.23M | 784.74M | 1.08B |
| Cash & ST investments | 636.63M | 563.36M | 490.90M | 874.65M | 762.18M | 981.53M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 660.98M | 582.32M | 577.14M | 899.42M | 789.02M | 1.10B |
| Total current liabilities | 33.73M | 52.59M | 50.70M | 70.70M | 51.81M | 63.79M |
| Short-term debt | 536.00K | 8.99M | 730.00K | 753.00K | 738.00K | 722.00K |
| Long-term debt | 20.69M | 12.35M | 20.89M | 49.94M | 50.44M | 242.16M |
| Total liabilities | 56,508,000.00 | 67,155,000.00 | 74,168,000.00 | 177,251,000.00 | 153,009,000.00 | 435,136,000.00 |
| Total equity | 604.47M | 515.17M | 502.97M | 722.17M | 636.01M | 662.10M |
| Retained earnings | -1.08B | -1.18B | -1.22B | -1.34B | -1.44B | -1.57B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -26.84M | -36.06M | -29.78M | -54.58M | -93.84M | -184.17M | -232.32M | -276.39M |
| Depreciation & amortization | 281.00K | 288.00K | 239.00K | 120.00K | 255.00K | 522.00K | 540.00K | 460.00K |
| Free cash flow | -27.29M | -36.14M | -29.82M | -54.92M | -94.64M | -185.07M | -232.83M | -276.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 44.53M | 2.48M | 25.10M | 114.24M | 291.87M | 125.07M | 453.66M | 352.20M |
| Ending cash balance | 32.61M | 24.85M | 45.90M | 42.30M | 155.58M | 102.83M | 99.59M | 212.38M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -92.65M | -75.37M | -84.61M | -23.75M | -119.65M | -105.32M |
| Depreciation & amortization | 117.00K | 113.00K | 110.00K | 120.00K | 121.00K | 117.00K |
| Free cash flow | -92.74M | -75.42M | -84.74M | -23.99M | -119.68M | -106.63M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 4.94M | 1.00K | 9.96M | 337.29M | 0 | 143.75M |
| Ending cash balance | 116.22M | 117.32M | 169.65M | 212.38M | 176.35M | 164.99M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -72.79 | -124.81 | -- | -- | -84.66 | -97.35 | -75.17 | -63.87 |
| ROA %i | -55.14 | -86.87 | -137.09 | -47.42 | -40.66 | -51.37 | -43.79 | -41.73 |
| ROIC %i | -58.89 | -97.97 | -- | -- | -84.67 | -98.87 | -78.65 | -63.78 |
| 5-year avg ROE %i | -- | -145.20 | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -379.56 | -919.93 | -10,495.90 | -2,680.05 | -7,301.81 | -75,123.25 | -88,378.48 | -476.58 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.71 | 2.92 | 12.14 | 14.68 | 12.93 | 18.26 | 15.43 | 12.65 |
| Quick ratioi | 9.28 | 2.64 | 11.96 | 14.48 | 12.73 | 17.93 | 14.99 | 12.37 |
| Debt / assetsi | 15.57 | 27.44 | 0.35 | 0.26 | 1.21 | 4.29 | 2.84 | 5.64 |
| LT debt / equityi | 15.59 | 27.47 | -- | -- | 1.84 | 8.58 | 4.26 | 8.46 |
| Interest coveragei | -36.46 | -49.15 | -216.94 | -26,470.00 | -266.23 | -127.71 | -87.62 | -68.24 |
| Revenue CAGR (3Y) %i | 48.94 | 10.16 | -35.99 | -29.30 | -26.49 | -33.13 | -53.29 | 241.95 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -76.27 | -104.91 | -73.67 | -63.87 | -79.16 | -86.93 |
| ROA %i | -47.16 | -58.92 | -45.47 | -41.73 | -50.20 | -46.08 |
| ROIC %i | -79.26 | -106.44 | -75.93 | -63.78 | -77.39 | -69.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -101,084.11 | -111,835.74 | -422.30 | -476.58 | -497.38 | -522.10 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 19.49 | 11.01 | 11.28 | 12.65 | 15.15 | 16.95 |
| Quick ratioi | 18.88 | 10.71 | 11.06 | 12.37 | 14.71 | 16.56 |
| Debt / assetsi | 3.21 | 3.66 | 3.75 | 5.64 | 6.49 | 22.14 |
| LT debt / equityi | 4.98 | 3.79 | 6.65 | 8.46 | 10.01 | 42.93 |
| Interest coveragei | -100.25 | -115.16 | -98.59 | -68.24 | -44.88 | -23.78 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Collaboration revenue - related parties is the largest reported line at 95.74% of revenue, across 2 reported segments.
- The next-largest line, Discovering, developing and commercializing potential best-in-class medicines for serious and rare, is a distant second at 4.26% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Collaboration revenue - related parties95.74%
Discovering, developing and commercializing potential best-in-class medicines for serious and rare4.26%
Quote time 2026-10-07 21:23:26 · For reference only, not investment advice and not tailored to your situation.